Jacobs Levy Equity Management
AXSM icon

Jacobs Levy Equity Management’s Axsome Therapeutics AXSM Stock Holding History

Jacobs Levy Equity Management’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-42,438
Closed -$4.39M – 1006
2019
Q4 		$4.39M Sell
42,438
-31,827
-43% -$1.29M 0.04% 396
2019
Q3 		$1.5M Hold
74,265
– – 0.02% 561
2019
Q2 		$1.91M Hold
74,265
– – 0.03% 531
2019
Q1 		$1.06M Sell
74,265
-9,900
-12% -$91.9K 0.02% 646
2018
Q4 		$237K Buy
84,165
+20,800
+33% +$68.4K ﹤0.01% 848
2018
Q3 		$219K Buy
+63,365
New +$188K ﹤0.01% 915

Other funds holding AXSM

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IAM
Iridian Asset Management Westport, Connecticut $247M AUM 20.65% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
ACM
Alethea Capital Management Mercer Island, Washington $195M AUM 51.17% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Jacobs Levy Equity Management's AXSM Position: Q1 2020 in Review

Jacobs Levy Equity Management sold out of Axsome Therapeutics (AXSM) in Q1 2020, closing a stake of 42,438 shares — an estimated $4.39M sold.

Jacobs Levy Equity Management first reported a position in AXSM in Q3 2018 and held it in 6 quarters. The position peaked at $4.39M in Q4 2019. 163 funds tracked by Wall St. Rank hold AXSM as of Q1 2020.

  • Jacobs Levy Equity Management reported no remaining Axsome Therapeutics position as of Q1 2020 after selling out during the quarter.
  • Jacobs Levy Equity Management sold 42,438 Axsome Therapeutics shares in Q1 2020, an estimated $4.39M.
  • Jacobs Levy Equity Management first reported a position in Axsome Therapeutics in Q3 2018 and held it in 6 quarters.
  • Jacobs Levy Equity Management's Axsome Therapeutics position peaked at $4.39M in Q4 2019.
  • 163 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q1 2020.

Based on Jacobs Levy Equity Management's 13F filing for Q1 2020, filed 15 May 2020.